Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

31 study showed that giving Imfinzi (durvalumab) as adjuvant therapy for stage IB-IIIA non-small cell lung cancer (NSCLC) was no better than placebo at extending disease-free survival (DFS).

The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which have helped drive sales of the PD-L1 inhibitor to $1.3 ...

Jan 30 (Reuters) - Private equity-backed Infinity Natural Resources raised $265 million on Thursday in its initial public offering in the U.S., the latest first-time share sale by an energy ...

While Tokyo will not likely hurry to rejig its forecasts, DeepSeek's seemingly leaner models have triggered a broad rethink of AI energy needs that the world's most resource-poor major economy ...

This guide will help you understand how NSCLC is treated, potential side effects, and how to navigate life beyond cancer.

which aligns with the circumstances observed in non-small cell lung cancer. In view of these findings, we believe that PSRC1 may be a potential therapeutic target for SCLC.” “Moreover ...

December 06, 2024--AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab ... the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in ...

Antero Resources Corporation, an independent oil and natural gas company, engages in the development, production, exploration, and acquisition of natural gas, natural gas liquids (NGLs), and oil ...

Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical ...